GRI (GRI Bio) Issuance of Debt: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GRI GRI Bio Inc GRI
28 GF Score
Price $1.76
! 1 Warning Sign
View Full Analysis

What is GRI Bio Issuance of Debt?

GRI Bio GRI +0.58% 28 Issuance of Debt is $0.00 Mil as of Jun. 2026. GuruFocus rates GRI with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

GRI Bio's Issuance of Debt for the three months ended in Jun. 2026 was $0.00 Mil.

GRI Bio's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

GRI Bio Issuance of Debt Related Terms

GRI Bio Issuance of Debt Historical Data

* Premium members only.

The historical data trend for GRI Bio's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GRI Bio Issuance of Debt Chart

GRI Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
0.50 1.50 1.25 0.00 0.00

GRI Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GRI
28GF Score
GRI Bio Inc GRI
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GRI Bio Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $0.00 Mil mean?
GRI Bio (GRI) has a Issuance of Debt of $0.00 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on GRI Bio and its competitors.
Is GRI Bio's Issuance of Debt too high?
GRI Bio's current Issuance of Debt is $0.00 Mil. Overall, GRI Bio has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does GRI Bio's Issuance of Debt compare to ISCO and VRAX?
GRI Bio's Issuance of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on GRI Bio and its competitors. GRI Bio's current Issuance of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRI Bio stock overvalued right now?
GRI Bio (GRI) has a current Issuance of Debt of $0.00 Mil. The current Issuance of Debt is $0.00 Mil. GRI Bio's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For GRI Bio (GRI), the current Issuance of Debt is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GRI Bio Business Description

Address 2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
28GF Score

Get the complete analysis for GRI

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.76
Price